AVITA Medical to Present at the Piper Sandler 36岬検奥燗nnual Healthcare Conference
AVITA Medical (NASDAQ: RCEL) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. CEO Jim Corbett will deliver a presentation on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. The company, which specializes in regenerative medicine and first-in-class devices for wound care management and skin restoration, will provide a live webcast of the fireside chat through their investor relations website. The presentation will remain available for replay after the event concludes.
AVITA Medical (NASDAQ: RCEL) ha annunciato la sua partecipazione al 36掳 Annual Healthcare Conference di Piper Sandler. Il CEO Jim Corbett presenter脿 un discorso marted矛 3 dicembre 2024, alle 11:30 a.m. ora orientale. L'azienda, specializzata in medicina rigenerativa e dispositivi innovativi per la gestione delle ferite e il ripristino della pelle, offrir脿 una diretta web del colloquio informale attraverso il proprio sito web delle relazioni con gli investitori. La presentazione rimarr脿 disponibile per la visione anche dopo la conclusione dell'evento.
AVITA Medical (NASDAQ: RCEL) ha anunciado su participaci贸n en la 36陋 Conferencia Anual de Atenci贸n M茅dica de Piper Sandler. El CEO Jim Corbett realizar谩 una presentaci贸n el martes 3 de diciembre de 2024, a las 11:30 a.m. hora del Este. La empresa, especializada en medicina regenerativa y dispositivos de primera clase para el manejo de heridas y la restauraci贸n de la piel, proporcionar谩 una transmisi贸n en vivo de la charla a trav茅s de su sitio web de relaciones con inversores. La presentaci贸n estar谩 disponible para su reproducci贸n despu茅s de que concluya el evento.
AVITA Medical (NASDAQ: RCEL)鞚� Piper Sandler 鞝�36須� 鞐半 鞚橂 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 歆� 旖旊ゴ氩�(Jim Corbett)鞚� 2024雲� 12鞗� 3鞚� 頇旍殧鞚� 霃欕秬 響滌鞁� 旮办 鞓れ爠 11:30鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞚� 須岇偓電� 鞛儩 鞚橂 氚� 靸侅矘 甏�毽檧 頂茧秬 氤奠洂鞚� 鞙勴暅 鞚茧 鞛レ箻毳� 鞝勲鞙茧 頃橂┌, 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 頇旍儊 毂勴寘鞚� 靸濎瓿勲ゼ 鞝滉车頃� 瓴冹瀰雼堧嫟. 氚滍憸 頉� 鞚措菠韸戈皜 膦呺霅� 頉勳棎霃� 雼れ嫓 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
AVITA Medical (NASDAQ: RCEL) a annonc茅 sa participation 脿 la 36e Conf茅rence Annuelle sur la Sant茅 de Piper Sandler. Le PDG Jim Corbett pr茅sentera une communication le mardi 3 d茅cembre 2024, 脿 11h30, heure de l'Est. L'entreprise, sp茅cialis茅e dans la m茅decine r茅g茅n茅rative et des dispositifs de premi猫re classe pour la gestion des plaies et la restauration de la peau, proposera un webinaire en direct de la discussion sur son site Web de relations avec les investisseurs. La pr茅sentation sera 茅galement disponible en rediffusion apr猫s la fin de l'茅v茅nement.
AVITA Medical (NASDAQ: RCEL) hat seine Teilnahme an der 36. j盲hrlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. CEO Jim Corbett wird am Dienstag, den 3. Dezember 2024, um 11:30 Uhr Eastern Time eine Pr盲sentation halten. Das Unternehmen, das auf regenerative Medizin und erstklassige Ger盲te f眉r die Wundversorgung und Hautrestaurierung spezialisiert ist, wird eine Live-Webcast der informellen Gespr盲chsrunde 眉ber seine Investor-Relations-Website anbieten. Die Pr盲sentation wird nach Abschluss der Veranstaltung auch als Wiederholung verf眉gbar sein.
- None.
- None.
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.
A live webcast of the fireside chat will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical庐 is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL庐 System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient鈥檚 own skin to create Spray-On Skin鈩� Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm庐, a biosynthetic wound matrix, and Cohealyx鈩�, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit鈥�.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When will AVITA Medical (RCEL) present at the Piper Sandler Healthcare Conference 2024?
How can I watch AVITA Medical's (RCEL) presentation at the Piper Sandler Conference?
What is AVITA Medical's (RCEL) main business focus?
Which stock exchanges is AVITA Medical listed on?
